condition found tbRes List
HDAC, Histone deacetylases: Click to Expand ⟱
Source:
Type:
Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped.
-Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation.
-HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer.
-HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells.
-HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis.
-HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type.
-While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes.
-HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases.
-HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells.
Scientific Papers found: Click to Expand⟱
3423- ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,
2663- AL,    Therapeutic Effect of Allicin on Glioblastoma
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG
BioAv↝, TumCCA↑, P53↑, HDAC↓, CSCs↓, ROS↑, ChemoSen↑, MGMT↓,
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
1156- And,    Exploring the potential of Andrographis paniculata for developing novel HDAC inhibitors: an in silico approach
- Analysis, NA, NA
HDAC↓,
1151- Api,    Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study
- in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
TumCCA↑, Apoptosis↑, HDAC↓, P21↑, BAX↑, TumCG↓, Bcl-2↓, Bax:Bcl2↑, HDAC1↓, HDAC3↓,
177- Api,    Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression
- in-vitro, BC, MDA-MB-231
Cyc↓, CycB↓, CDK1↓, P21↑, PCNA↝, HDAC↓,
2664- Api,    Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents
- Review, Var, NA
HDAC↓,
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoP↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
2631- Api,    Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells
- in-vivo, GC, NA - in-vitro, GC, AGS
ER Stress↑, Hif1a↓, EZH2↓, HDAC↓, TumAuto↑, p‑mTOR↓, AMPKα↑, GRP78/BiP↑, ROS↑, MMP↓, Ca+2↑, ATF4↑, CHOP↑,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, eff↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, eff↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
1561- Api,    Apigenin Reactivates Nrf2 Anti-oxidative Stress Signaling in Mouse Skin Epidermal JB6 P + Cells Through Epigenetics Modifications
- in-vivo, Nor, JB6
*NRF2↑, *DNMT1↓, *DNMT3A↓, *HDAC↓, *AntiCan↑,
1433- Ash,  SFN,    A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
eff↑, Bcl-2↓, BAX↑, tumCV↓, DNMT1↓, DNMT3A↓, HDAC↓,
3175- Ash,  SFN,    Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
DNMTs↓, HDAC↓, eff↑,
1080- BA,    Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition
- in-vitro, CRC, HT-29
HDAC↓, TNF-α↓, COX2↓,
2047- BA,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
2050- BA,    The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells
- in-vitro, BC, MCF-7
eff↑, HDAC↓, TumCG↓,
2697- BBR,    Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes
- Analysis, Var, NA
HDAC↓,
2698- BBR,    A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine
- Analysis, BC, MDA-MB-231
HDAC↓, Akt↓, mTOR↓, ER Stress↑, TumAuto↑, AMPK↑, mTOR∅, HDAC∅, ac‑α-tubulin↑,
2699- BBR,    Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line
- in-vitro, Lung, A549
HDAC↓, TumCCA↑, TNF-α↓, COX2↓, MMP2↓, MMP9↓, P21↑, P53↑, Casp↑, ac‑H3↑, ac‑H4↑, ROS↑, MMP↓,
2764- BetA,    In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan
- Analysis, Var, NA
HDAC↓,
696- Bor,    Nothing Boring About Boron
- Review, Var, NA
*hs-CRP↓, *TNF-α↓, *SOD↑, *Catalase↑, *GPx↑, *cognitive↑, *memory↑, *Risk↓, *SAM-e↑, *NAD↝, *ATP↝, *Ca+2↝, HDAC↓, TumVol↓, IGF-1↓, PSA↓, Cyc↓, TumCMig↓, *serineP↓, HIF-1↓, *ChemoSideEff↓, *VitD↑, *Mag↑, *eff↑, Risk↓, *Inflam↓, *neuroP↑, *Calcium↑, *BMD↑, *chemoP↑, AntiCan↑, *Dose↑, *Dose↝, *BMPs↑, *testos↑, angioG↓, Apoptosis↑, *selectivity↑,
3522- Bor,    The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry
- Review, Var, NA
Hif1a↓, HDAC↓, *CXCR2↑, ROS↑,
3523- Bor,    Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors
- in-vitro, Var, NA
HDAC↓,
2794- CHr,    An updated review on the versatile role of chrysin in neurological diseases: Chemistry, pharmacology, and drug delivery approaches
- Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *IL1β↓, *TNF-α↓, *COX2↓, *iNOS↓, *NF-kB↓, *JNK↓, *HDAC↓, *GSK‐3β↓, *IFN-γ↓, *IL17↓, *GSH↑, *NRF2↑, *HO-1↑, *SOD↑, *MDA↓, *NO↓, *GPx↑, *TBARS↓, *AChE↓, *GR↑, *Catalase↑, *VitC↑, *memory↑, *lipid-P↓, *ROS↓,
2798- CHr,    Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
HDAC↓, HDAC8↓, TumCG↓, Diff↑,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1↓, hTERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1↓, hTERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
1505- CUR,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
TumCCA↑, Apoptosis↑, DNMTs↓, HDAC↓, HATs↓, TumCP↓, p300↓, HDAC1↓, HDAC3↓, HDAC8↓, NF-kB↓,
163- CUR,    Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells
- in-vitro, Pca, LNCaP
MeCP2↓, Neurog1↑, HDAC↓,
1863- dietFMD,  Chemo,    Effect of fasting on cancer: A narrative review of scientific evidence
- Review, Var, NA
eff↑, ChemoSideEff↓, ChemoSen↑, Insulin↓, HDAC↓, IGF-1↓, STAT5↓, BG↓, MAPK↓, HO-1↓, ATG3↑, Beclin-1↑, p62↑, SIRT1↑, LAMP2↑, OXPHOS↑, ROS↑, P53↑, DNAdam↑, TumCD↑, ATP↑, Treg lymp↓, M2 MC↓, CD8+↑, Glycolysis↓, GutMicro↑, GutMicro↑, Warburg↓, Dose↝,
672- EGCG,    Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer
- Review, NA, NA
DNMT1↓, HDAC↓, G9a↓, PRC2↓, DNMT3A↓, 67LR↓, Apoptosis↑, TumCCA↑,
3201- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
3229- EGCG,    Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells
- in-vitro, Nor, HMEC - in-vitro, Nor, HUVECs
HDAC↓,
3230- EGCG,    Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, DNMTs↓,
3231- EGCG,    Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy
- in-vitro, Nor, NA
*HDAC↓, *cardioP↑, *Nrf1↑, *PGC-1α↓,
3235- EGCG,    (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells
- in-vivo, Cerv, HeLa
DNMTs↓, HDAC↓,
3236- EGCG,  BA,    Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate
- in-vitro, Colon, RKO - in-vitro, Colon, HCT116 - in-vitro, Colon, HT29
Apoptosis↑, TumCCA?, HDAC1↓, DNMT1↓, survivin↓, HDAC↓, P21↑, NF-kB↑, γH2AX↑, ac‑H3↑, DNAdam↑,
3237- EGCG,    (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression
- in-vivo, AD, NA
*HDAC↓, *Aβ↓, cognitive↑,
1435- GEN,  SFN,    The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
DNMTs↓, HDAC↓, eff↑, TumCCA↑, HMTs↓, HDAC2↓, HDAC3↓, KLF4↓, hTERT↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2875- HNK,    Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460 - in-vitro, SCC, H226
HDAC↓, tumCV↓, TumCCA↑, cycD1↓, ac‑H3↑, ac‑H4↑, selectivity↑, CDK2↓, CDK4↓,
1064- LT,  Cisplatin,    Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells
- vitro+vivo, Lung, LNM35 - in-vitro, CRC, HT-29 - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Casp3↑, Casp7↑, HDAC↓,
2915- LT,    Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells
- in-vitro, Colon, HT29 - in-vitro, CRC, SNU-407 - in-vitro, Nor, FHC
DNMTs↓, TET1↑, NRF2↑, HDAC↓, tumCV↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, ROS↓, GSS↑, Catalase↑, HO-1↑, DNMT1↓, DNMT3A↓, TET1↑, TET3↑, TET2↓, P53↑, P21↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,
1196- MAG,    2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
- in-vitro, HCC, NA
TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,
2031- PB,    Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model
- in-vivo, AD, NA
*neuroP↑, *HDAC↓, *ChemChap↑,
2035- PB,    Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease
- in-vitro, Nor, glial - in-vivo, NA, NA
*ROS↓, *Inflam↑, *P21↓, *antiOx↑, *GSH↑, *NF-kB↓, *neuroP↑, *HDAC↓, *iNOS↓, *TNF-α↓, *IL1β↓, *LDL↓, ROS↓,
2049- PB,    Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
- Review, Var, NA
HDAC↓, ac‑H3↑, ac‑H4↑, ac‑H3↑, eff↝, toxicity↓,
2061- PB,  Chemo,    Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells
- in-vitro, PC, PANC1 - in-vitro, PC, COLO357 - in-vitro, PC, Bxpc-3
HDAC↓, Apoptosis↑, eff↑, selectivity↑, TumCCA↑, eff↑, selectivity↑,
2054- PB,    Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis
- in-vitro, EC, ISH - in-vitro, EC, HEC1B
Ferroptosis↑, xCT↓, RBM3↑, HDAC↓, ROS↑,
2052- PB,    Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications
- Review, NA, NA
*HDAC↓, *Half-Life↑, *Half-Life↑, *lipoGen↓, *ER Stress↓, *FAO↑, *ROS↓, *BioAv↑,
2048- PB,    Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo
- in-vitro, OS, CAL27 - in-vitro, Oral, HSC3 - in-vitro, OS, SCC4 - in-vivo, NA, NA
*NH3↓, *HDAC↓, *ER Stress↓, Apoptosis?, Bcl-2↓, cl‑Casp3↑, TGF-β↑, N-cadherin↓, E-cadherin↑, TumVol↓, eff↑,
2046- PB,    Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-468 - in-vitro, Nor, MCF10
Apoptosis↑, i-ROS?, Casp↑, MMP?, selectivity↑, *ROS∅, HDAC↓, DNArepair↓, Casp3↑, Casp8↑, *toxicity↓, TumCCA↑,
2045- PB,    Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line
- in-vitro, GBM, LN229 - in-vitro, GBM, LN-18
HDAC↓, TumCG↓, TumCCA↑, P21↑, Bcl-2↓, Bcl-xL↓, BioAv↑,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
2042- PB,    Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury
- in-vitro, Nor, NA
*HDAC↓, *toxicity↓, *LDH↓, *SOD2↑, *ROS↓, *cardioP↑, *antiOx↑,
2039- PB,    TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment
- in-vitro, Lung, A549 - in-vitro, Nor, HEK293
TXNIP↑, Casp3↑, Casp7↑, mt-ROS↑, GlucoseCon↓, TumCP↓, TumCD↑, IGF-2↑, HDAC↓, ROS⇅,
2029- PB,    Phenylbutyric Acid: simple structure - multiple effects
- Review, Var, NA
NH3↓, HDAC↓, ChemChap↑,
2030- PB,    4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor
- Review, Nor, NA
*HDAC↓, *neuroP↑, *ChemChap↑,
2074- PB,  Chemo,    The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
- in-vitro, Lung, A549 - in-vitro, Lung, Calu-6 - in-vitro, Lung, H1650
TumCG↓, eff↑, ChemoSen↑, HDAC↓,
2075- PB,  Chemo,    Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival
- Trial, CRC, NA
OS↑, HDAC↓,
2067- PB,    Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer
- in-vitro, PC, NA
HDAC↓, HATs↑,
2064- PB,  Rad,    Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
Bcl-xL↓, Cav1↓, VEGF↓, RadioS↑, chemoP↑, HDAC↓, *toxicity↓, Diff↑, Prot↓,
2026- PB,    Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
- Trial, GBM, NA
Dose↝, Dose↑, Dose↝, OS↑, HDAC↓, TumCCA↑, P21↑, other↝, BioAv↑, eff↑,
2027- PB,    Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
- Trial, Var, NA
TumCG↓, Dose↝, toxicity↓, Dose↝, HDAC↓, OS↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
2077- PB,    Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells
- in-vitro, Liver, HUH7
miR-22↑, SIRT1↓, ROS↑, Cyt‑c↑, Casp3↑, eff↓, TumCG↓, TumCP↓, HDAC↓, SIRT1↓, CD44↓, proMMP2↓, MMP↓, SOD↓,
998- PB,    Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect
- in-vivo, NA, NA
p‑PDH↓, PDH↑, PDK1↓, HDAC↓, Glycolysis↓, MMP↓, Apoptosis↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1↓, CycB↓, CDK2↓, P21↑, p27↑, hTERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
1660- PBG,    Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
- Review, Var, NA
MMPs↓, angioG↓, TumMeta↓, TumCCA↑, Apoptosis↑, ChemoSideEff↓, eff∅, HDAC↓, PTEN↑, p‑PTEN↓, p‑Akt↓, Casp3↑, p‑ERK↑, p‑FAK↑, Dose?, Akt↓, GSK‐3β↓, FOXO3↓, eff↑, IL2↑, IL10↑, NF-kB↓, VEGF↓, mtDam↑, ER Stress↑, AST↓, ALAT↓, ALP↓, COX2↓, eff↑, Bax:Bcl2↑,
1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
ROS↑, Apoptosis↑, MMP↓, TumCCA↑, DNAdam↑, STAT3↓, Akt↓, PCNA↓, Ki-67↓, cycD1↓, Bcl-2↓, K17↓, HDAC↓, ROS↑, *IL1β↓, *IL6↓, *TNF-α↓, *IL17↓, *IL22↓,
3357- QC,    The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes
- in-vitro, AML, HL-60 - NA, NA, U937
DNMT1↓, DNMT3A↓, HDAC↓, ac‑H3↑, ac‑H4↑, BAX↑, APAF1↑, BNIP3↑, STAT3↑,
3359- QC,    Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells
- in-vitro, Cerv, HeLa
DNMTs↓, HDAC↓, HMTs↓, DNMT3A↓, EZH2↓, HDAC1↓, HDAC2↓, HDAC6↓, HDAC11↓, G9a↓, TIMP3↑, PTEN↑, SOCS1↑,
3360- QC,    Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy
- Review, Var, NA
HDAC↓, DNMTs↓, HMTs↓, Let-7↑, NOTCH↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
882- RES,    Resveratrol: A Double-Edged Sword in Health Benefits
- Review, NA, NA
AntiTum↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Bcl-xL↓, P53↑, NAF1↓, NRF2↑, ROS↑, Apoptosis↑, HDAC↓, TumCCA↑, TumAuto↑, angioG↓, iNOS↓,
883- RES,    Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
HDAC↓, TumCCA↑, Apoptosis↑, angioG↓, ROS↑,
1506- RES,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
DNMTs↓, BRCA1↑, HDAC↓, SIRT1↑, p300↓, survivin↓, HDAC1↓, HDAC3↓, HDAC8↓,
2040- SAHA,    The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
- in-vitro, Pca, LNCaP - in-vitro, CRC, T24 - in-vitro, BC, MCF-7
HDAC↓, TumCG↓, Diff↑, Apoptosis↑, TXNIP↑,
1062- Sel,    Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
- in-vitro, GBM, LN229 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HDAC↓, TumCP↓, TumCCA↑, Apoptosis↑, Casp3↝, MMP2↓, *BioAv↝,
1061- SFN,    Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors
- vitro+vivo, NA, NA
AntiTum↑, HDAC↓,
2554- SFN,    Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm
- Review, Var, NA
Dose↝, chemoP↑, *NQO1↑, *GSTA1↑, HDAC↓, NF-kB↓,
2555- SFN,    Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis
- Review, Var, NA
chemoP↑, HDAC↓, TumCCA↑, Apoptosis↑, Mets↑, *NRF2↑, ROS⇅,
2556- SFN,    The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review
- Review, Var, NA
chemoP↑, HDAC↓, Hif1a↓, angioG↓, CYP1A1↓, eff↑, BioAv↑,
3192- SFN,    Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention
- in-vitro, Pca, PC3
Sp1/3/4↓, selectivity↑, NRF2↑, HDAC↓, DNMTs↓, TumCCA↑, selectivity↑, HO-1↑, NQO1↑, CDK2↓, TumCP↓, BID↑, Smad1↑, Diablo↑, ICAD↑, Cyt‑c↑, IAP1↑, HSP27↑, *Cyt‑c↓, *IAP1↓, *HSP27↓, survivin↓, CDK4↓, VEGF↓, AR↓,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1722- SFN,    Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems
- Review, Var, NA
TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,
1725- SFN,    Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway
- Review, Var, NA
*toxicity∅, AntiCan↑, antiOx↑, NRF2↑, DNMTs↓, HDAC↓, Hif1a↓, VEGF↓, P21↑, TumCCA↑, ac‑H3↑, ac‑H4↑, DNAdam↑, Dose↝,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
1724- SFN,    Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials
- Review, Var, NA
antiOx↑, NRF2↑, HDAC↓, neuroP↑,
1494- SFN,  doxoR,    Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model
- in-vivo, BC, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
CardioT↓, *GSH↑, *ROS↓, *NRF2↑, NRF2∅, HDAC↓, DNMTs↓, Casp3↑, ER-α36↓, Remission↑, eff↑, ROS↑, selectivity?,
1484- SFN,    Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action
- Review, Var, NA - Review, AD, NA
neuroP↑, AntiCan↑, NRF2↑, HDAC↓, eff↑, *ROS↓, neuroP↑, HDAC↓, *toxicity∅, BioAv↑, eff↓, cycD1↓, CDK4↓, p‑RB1↓, Glycolysis↓, miR-30a-5p↑, TumCCA↑, TumCG↓, TumMeta↓, eff↑, ChemoSen↑, RadioS↑, CardioT↓, angioG↓, Hif1a↓, VEGF↓, *BioAv?, *Half-Life∅,
1430- SFN,    Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy
- Trial, BC, NA
*HDAC3↓, HDAC↓, *toxicity↓,
1428- SFN,    Broccoli or Sulforaphane: Is It the Source or Dose That Matters?
- Review, NA, NA
HDAC↓, NRF2↑,
1454- SFN,    Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract
- Human, Nor, NA
*HDAC↓, *eff↑, *eff↑, *eff↑, *BioAv↑, *BioAv↑,
1453- SFN,    Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCP↓, TumCCA↑, H3↑, H4↑, HDAC↓, CDK1↑, CDK2↑, p19↑, *BioAv↑,
1452- SFN,    Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells
- in-vitro, GC, AGS
MMP9↓, p38↓, ERK↓, AP-1↓, ROS↓, NF-kB↓, TumCI↓, MMP9↓, HDAC↓, Glycolysis↓, Hif1a↓, *memory↑, *cognitive↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1496- SFN,  VitD3,    Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells
- in-vitro, CRC, Caco-2
eff↑, VDR↑, CYP11A1↓, HDAC↓,
1497- SFN,    Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells
- in-vitro, Nor, PrEC - in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
HDAC↓, selectivity↑, TumCCA↑, Apoptosis↑, selectivity↑, H3↑, P21↑, selectivity↑,
1500- SFN,    A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase
- in-vitro, Nor, HEK293 - in-vitro, CRC, HCT116
HDAC↓, P21↑, TOPflash↑,
1502- SFN,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
HDAC↓, AntiCan↑, DNMTs↓, hTERT↓, selectivity↑,
1437- SFN,    Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition
- Review, NA, NA
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, eff↑, ac‑HSP90↑, DNMT1↓, DNMT3A↓, hTERT↓, NRF2↑, HO-1↑, NQO1↑, miR-155↓, miR-200c↑, SOX9↓, *toxicity↓,
1458- SFN,    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
- Review, Bladder, NA
HDAC↓, eff↓, TumW↓, TumW↓, angioG↓, *toxicity↓, GutMicro↝, AntiCan↑, ROS↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8∅, cl‑PARP↑, TRAIL↑, DR5↑, eff↓, NRF2↑, ER Stress↑, COX2↓, EGFR↓, HER2/EBBR2↓, ChemoSen↑, NF-kB↓, TumCCA?, p‑Akt↓, p‑mTOR↓, p70S6↓, p19↑, P21↑, CD44↓,
2164- SFN,  dietP,    Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice
- in-vitro, Pca, NA
HDAC↓, Dose↝, Risk↓, TumCP↓, H3↓,
1508- SFN,    Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment
- Review, Var, NA
*BioAv↑, HDAC↓, TumCCA↓, eff↓, Wnt↓, β-catenin/ZEB1↓, Casp12?, Bcl-2↓, cl‑PARP↑, Bax:Bcl2↑, IAP1↓, Casp3↑, Casp9↑, Telomerase↓, hTERT↓, ROS?, DNMTs↓, angioG↓, VEGF↓, Hif1a↓, cMYB↓, MMP1↓, MMP2↓, MMP9↓, ERK↑, E-cadherin↑, CD44↓, MMP2↓, eff↑, IL2↑, IFN-γ↑, IL1β↓, IL6↓, TNF-α↓, NF-kB↓, ERK↓, NRF2↑, RadioS↑, ChemoSideEff↓,
1507- SFN,    Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects
- in-vivo, Colon, NA - Human, Nor, NA
TumCG↓, HDAC↓, *BioAv↑, Dose∅, Half-Life∅,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, *NA↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3322- SIL,    Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,
2119- TQ,    Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant
- Review, Var, NA
*ROS↓, ROS↑, chemoP↑, RenoP↑, hepatoP↑, NLRP3↓, neuroP↑, NF-kB↓, P21↑, HDAC↓, Apoptosis↑, TumCP↓, GSH↓, GADD45A↑, GSK‐3β↑,
2103- TQ,    Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells
- in-vitro, PC, Hs766t - in-vitro, PC, MIA PaCa-2
MCP1↓, TNF-α↓, IL1β↓, COX2↓, NF-kB↓, HDAC↓, P21↑,
2102- TQ,    A review on therapeutic potential of Nigella sativa: A miracle herb
- Review, Var, NA
angioG↓, NF-kB↓, PPARγ↓, Bcl-2↓, Bcl-xL↓, MUC4↓, cJun↑, p38↑, P21↑, HDAC↓, radioP↑, hepatoP↑,
2101- TQ,    HDAC inhibition by Nigella sativa L. sprouts extract in hepatocellular carcinoma: an approach to study anti-cancer potential
- Study, HCC, NA
HDAC↓, eff↑, eff↑, AntiCan↑,
2100- TQ,    Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant
- Review, NA, NA
ROS⇅, *antiOx↑, *SOD↑, *MPO↑, *neuroP↑, *chemoP↑, *radioP↑, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, Bcl-xL↓, survivin↓, COX2↓, MMP9↓, VEGF↓, ROS↑, P21↑, HDAC↓, GSH↓, GADD45A↑, AIF↑, STAT3↓,
2105- TQ,    Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation
- in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, Hs766t - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, P53↑, Bcl-2↓, P21↑, ac‑H4↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, TumVol↓,
2108- TQ,    Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa
- Review, Var, NA
HDAC↓, TumCCA↑, cycD1↓, p16↑, P53↑, Bax:Bcl2↑, Bcl-xL↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, survivin↓, COX2↓, cMyc↓, ROS↑, Casp3↑, cl‑PARP↑, Cyt‑c↑, STAT3↓,
2353- TQ,    The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies
- Review, PC, NA
BioAv↝, BioAv↑, MUC4↓, PKM2↓, eff↑, TumVol↓, HDAC↓, NF-kB↓, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, COX2↓, PGE1↓,
3421- TQ,    Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer
- Analysis, Nor, NA - in-vivo, Nor, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, HaCaT
HDAC↓, P21↑, Maspin↑, BAX↑, B2M↓, TumCCA↑, selectivity↑, *toxicity↓, TumCMig↓, TumCP↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
3426- TQ,    Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms
- in-vitro, BC, MDA-MB-468 - in-vitro, ALL, JK
UHRF1↓, DNMT1↓, DNMT3A↓, DNMTs↓, HDAC1↓, HDAC4↓, HDAC↓, DLC1↑, PPARγ↑, FOXO↑, TET2↑, CYP1B1↑, G9a↓,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 126

Results for Effect on Cancer/Diseased Cells:
67LR↓,1,   AIF↑,3,   Akt↓,12,   p‑Akt↓,5,   AKT1↓,1,   ALAT↓,2,   ALDH↓,1,   ALDH1A1↓,1,   ALP↓,2,   AMPK↑,3,   AMPKα↑,1,   angioG↓,18,   AntiAg↓,1,   AntiCan↑,9,   antiOx↓,1,   antiOx↑,2,   AntiTum↑,3,   AP-1↓,2,   APAF1↑,2,   Apoptosis?,1,   Apoptosis↑,27,   AR↓,4,   ASC↓,1,   ASK1↑,1,   AST↓,1,   ATF4↑,1,   ATG3↑,1,   ATG5↑,1,   ATG7↑,1,   ATP↓,2,   ATP↑,1,   AXL↓,1,   B2M↓,1,   Bak↑,2,   BAX↑,17,   BAX⇅,1,   Bax:Bcl2↑,7,   Bcl-2↓,19,   Bcl-xL↓,13,   Beclin-1↑,1,   BG↓,1,   BID↑,1,   BIM↓,1,   BioAv↓,5,   BioAv↑,8,   BioAv↝,5,   BioEnh↑,1,   BMI1↓,1,   BMPs↑,1,   BNIP3↑,1,   BRCA1↓,1,   BRCA1↑,2,   CA↓,1,   Ca+2↑,5,   cachexia↓,1,   cardioP↑,3,   CardioT↓,2,   Casp↑,5,   Casp1↓,1,   Casp12?,1,   Casp12↑,1,   Casp3↓,1,   Casp3↑,24,   Casp3↝,1,   cl‑Casp3↑,3,   Casp7↑,4,   Casp8↑,4,   Casp8∅,1,   Casp9↑,12,   cl‑Casp9↑,1,   Catalase↓,2,   Catalase↑,1,   Cav1↓,1,   CD133↓,3,   CD31↓,1,   CD34↓,2,   CD44↓,5,   CD8+↑,1,   CDC25↓,1,   Cdc42↓,1,   CDH1↑,1,   CDK1↓,1,   CDK1↑,2,   CDK2↓,7,   CDK2↑,1,   CDK4↓,8,   CDK6↓,3,   CDKN1C↑,1,   CEA↓,1,   cFLIP↓,2,   cFos↑,1,   ChemChap↑,1,   chemoP↑,11,   ChemoSen↑,20,   ChemoSideEff↓,3,   p‑Chk2↑,1,   CHOP↑,4,   cl‑CHOP↑,1,   cJun↑,2,   CK2↓,2,   CLDN1↓,3,   CLDN2↓,1,   p‑cMET↑,1,   cMYB↓,1,   cMyc↓,6,   cognitive↑,1,   COX2↓,18,   COX2↑,2,   CSCs↓,5,   cSrc↓,1,   CXCL12↓,1,   CXCR4↓,3,   Cyc↓,2,   cycA1↓,1,   CycB↓,2,   cycD1↓,12,   cycD1↑,1,   CycD3↓,1,   cycE↓,1,   CYP11A1↓,1,   CYP1A1↓,3,   CYP1B1↑,1,   CYP3A4↓,1,   Cyt‑c↓,1,   Cyt‑c↑,16,   Cyt‑c↝,1,   Diablo↑,3,   Diff↑,3,   DLC1↑,1,   DNAdam↑,7,   DNArepair↓,2,   DNMT1↓,12,   DNMT3A↓,10,   DNMTs↓,20,   Dose?,2,   Dose↑,1,   Dose↝,14,   Dose∅,2,   DR5↑,3,   E-cadherin↓,1,   E-cadherin↑,11,   EF-1α↓,1,   eff↓,7,   eff↑,43,   eff↝,3,   eff∅,1,   EGFR↓,7,   EGFR↑,1,   eIF2α↑,1,   p‑eIF2α↑,2,   EMT?,1,   EMT↓,14,   eNOS↓,1,   ER Stress↓,1,   ER Stress↑,8,   ER-α36↓,1,   ER(estro)↓,1,   ERK↓,7,   ERK↑,2,   p‑ERK↓,2,   p‑ERK↑,1,   EZH2↓,5,   FAK↓,8,   p‑FAK↑,1,   Fas↑,1,   FasL↑,1,   Ferroptosis↑,1,   Fibronectin↓,1,   FOXO↑,2,   FOXO3↓,1,   FOXO3↑,2,   G9a↓,3,   GADD45A↑,2,   Gli↓,1,   Gli1↓,1,   glucoNG↓,1,   GlucoseCon↓,2,   GLUT1↓,2,   GlutMet↓,1,   Glycolysis↓,5,   GPx↓,1,   GRP78/BiP↓,1,   GRP78/BiP↑,4,   GSH↓,6,   GSH↑,1,   GSK‐3β↓,1,   GSK‐3β↑,1,   p‑GSK‐3β↓,2,   GSR↓,1,   GSS↑,1,   GSTA1↑,1,   GSTs↓,1,   GutMicro↑,2,   GutMicro↝,1,   H3↓,2,   H3↑,3,   ac‑H3↓,1,   ac‑H3↑,9,   H4↓,1,   H4↑,3,   ac‑H4↓,1,   ac‑H4↑,7,   Half-Life↓,2,   Half-Life↝,2,   Half-Life∅,1,   HATs↓,4,   HATs↑,6,   HDAC↓,116,   HDAC∅,1,   HDAC1↓,13,   HDAC11↓,1,   HDAC2↓,6,   HDAC3↓,9,   HDAC4↓,2,   HDAC6↓,1,   HDAC8↓,6,   hepatoP↑,6,   HER2/EBBR2↓,4,   HGF/c-Met↓,2,   HIF-1↓,1,   Hif1a↓,19,   HK2↓,4,   HMTs↓,3,   HMTs↑,1,   HO-1↓,4,   HO-1↑,4,   HSP27↑,2,   HSP90↓,1,   ac‑HSP90↑,1,   hTERT↓,9,   IAP1↓,3,   IAP1↑,1,   IAP2↓,2,   ICAD↑,1,   ICAM-1↓,1,   IFN-γ↑,2,   IGF-1↓,3,   IGF-2↑,1,   IGFBP3↑,2,   Igs↑,1,   IKKα↓,2,   IL1↓,1,   IL10↓,3,   IL10↑,1,   IL18↓,1,   IL1β↓,4,   IL2↓,1,   IL2↑,4,   IL6↓,5,   IL8↓,2,   Inflam↓,3,   iNOS↓,3,   Insulin↓,1,   ITGB1↓,1,   JAK2↓,1,   JNK↓,1,   JNK↑,3,   p‑JNK↑,1,   Jun↓,1,   K17↓,1,   Ki-67↓,5,   KLF4↓,1,   lactateProd↓,1,   LAMP2↑,1,   LC3II↑,4,   LDH↓,1,   LDL↓,1,   Let-7↑,1,   lipid-P↓,2,   lipid-P↑,1,   LOX1↓,1,   M2 MC↓,1,   MAPK↓,6,   MAPK↑,2,   Maspin↑,2,   Mcl-1↓,2,   Mcl-1↑,1,   MCP1↓,2,   MDM2↑,1,   p‑MDM2↓,1,   MDSCs↓,1,   MeCP2↓,1,   MEK↓,1,   MET↓,1,   p‑MET↓,1,   Mets↑,1,   MGMT↓,1,   miR-139-5p↑,1,   miR-155↓,1,   miR-200c↑,1,   miR-203↑,1,   miR-22↑,1,   miR-30a-5p↑,1,   MMP?,1,   MMP↓,15,   MMP↑,1,   MMP-10↓,1,   MMP1↓,1,   MMP2↓,15,   proMMP2↓,1,   MMP9↓,17,   MMPs↓,9,   mtDam↑,1,   mTOR↓,7,   mTOR↑,1,   mTOR∅,1,   p‑mTOR↓,3,   mTORC1↓,1,   MUC4↓,3,   N-cadherin↓,5,   NADPH↑,1,   NAF1↓,1,   Nanog↓,3,   Nestin↓,2,   Neurog1↑,1,   neuroP↑,7,   NF-kB↓,23,   NF-kB↑,1,   NH3↓,1,   NHE1↓,1,   NK cell↑,1,   NLRP3↓,2,   NO↓,1,   NO↑,1,   NOTCH↓,4,   NOTCH1↓,2,   NOTCH1↑,1,   NOTCH3↓,1,   NQO1?,1,   NQO1↓,1,   NQO1↑,2,   NRF2↓,4,   NRF2↑,13,   NRF2∅,1,   NSE↓,1,   OCT4↓,3,   OS↑,5,   other?,1,   other↝,1,   OXPHOS↑,1,   mt-OXPHOS↓,1,   P-gp↓,1,   p16↑,2,   p19↑,2,   P21?,1,   P21↑,24,   p27↑,6,   p300↓,2,   p38↓,1,   p38↑,3,   p‑p38↑,2,   P450↓,1,   P53↑,15,   p62↓,1,   p62↑,1,   p65↓,1,   p‑p65↓,1,   p70S6↓,1,   PARK2↑,1,   PARP↑,3,   cl‑PARP↑,8,   PARP1↑,1,   PCNA↓,7,   PCNA↝,1,   PD-1↓,1,   PD-L1↓,1,   PDGF↓,2,   PDH↑,1,   p‑PDH↓,1,   PDK1↓,2,   p‑PERK↑,1,   PGE1↓,1,   PGE2↓,3,   PI3K↓,8,   p‑PI3K↓,2,   PINK1↑,1,   PKCδ↓,1,   PKM2↓,2,   PPARα↓,1,   cl‑PPARα↓,1,   PPARγ↓,2,   PPARγ↑,1,   pRB↑,1,   PRC2↓,1,   Prot↓,1,   PSA↓,2,   PTEN↓,1,   PTEN↑,7,   p‑PTEN↓,1,   Rac1↓,1,   radioP↑,1,   RadioS↑,7,   Raf↓,1,   c-Raf↓,1,   RARβ↑,1,   RAS↑,1,   p‑RB1↓,2,   RBM3↑,1,   Remission↑,1,   RenoP↑,3,   Rho↓,1,   Risk↓,2,   ROS?,1,   ROS↓,6,   ROS↑,34,   ROS⇅,4,   i-ROS?,1,   mt-ROS↑,1,   selectivity?,1,   selectivity↑,18,   Shh↓,2,   SIRT1↓,6,   SIRT1↑,3,   SIRT3↓,1,   SIRT3↑,1,   SIRT6↓,1,   Slug↓,1,   Smad1↑,1,   Smo↓,1,   Snail↓,5,   SOCS1↑,1,   SOD↓,3,   SOD2↓,1,   SOX2↓,1,   SOX4↓,1,   SOX9↓,1,   Sp1/3/4↓,1,   p‑Src↓,1,   SREBP1↓,1,   STAT3↓,10,   STAT3↑,1,   p‑STAT3↓,3,   p‑STAT3↑,1,   STAT5↓,1,   p‑STAT6↓,1,   survivin↓,14,   Telomerase↓,7,   TET1↑,3,   TET2↓,1,   TET2↑,2,   TET3↑,1,   TGF-β↓,3,   TGF-β↑,2,   TIMP1↑,1,   TIMP2↑,1,   TIMP3↑,1,   TLR4↓,1,   TNF-α↓,7,   TOP1↓,1,   TOPflash↑,1,   toxicity↓,2,   toxicity↝,1,   toxicity∅,1,   TRAIL↑,1,   Treg lymp↓,1,   TSP-1↑,1,   TumAuto↑,4,   TumCCA?,2,   TumCCA↓,1,   TumCCA↑,37,   TumCD↑,2,   TumCG↓,16,   TumCI?,1,   TumCI↓,7,   TumCMig↓,10,   TumCP↓,14,   tumCV↓,6,   TumMeta↓,10,   TumVol↓,5,   TumW↓,2,   TUNEL↑,1,   Twist↓,7,   TXNIP↑,2,   Tyro3↓,1,   UHRF1↓,1,   uPA↓,6,   UPR↑,1,   VDR↑,1,   VEGF↓,21,   VEGFR2↓,5,   Vim↓,5,   Vim↑,1,   VitC↓,1,   VitE↓,1,   Warburg↓,2,   Wnt↓,3,   XBP-1↓,1,   xCT↓,1,   XIAP↓,8,   YAP/TEAD↓,1,   Zeb1↓,6,   ZO-1↑,1,   ac‑α-tubulin↑,1,   β-catenin/ZEB1↓,5,   β-catenin/ZEB1↑,1,   γH2AX↑,1,  
Total Targets: 496

Results for Effect on Normal Cells:
AChE↓,1,   ALAT↓,1,   ALP↓,1,   AntiCan↑,3,   antiOx↑,10,   AP-1↓,1,   Apoptosis↓,1,   AST↓,2,   ATP↝,1,   Aβ↓,1,   BBB↑,2,   BioAv?,1,   BioAv↓,6,   BioAv↑,7,   BioAv↝,2,   BMD↑,1,   BMPs↑,1,   Ca+2↝,1,   Calcium↑,1,   cardioP↑,4,   Casp3↓,2,   Catalase↑,6,   ChemChap↑,2,   chemoP↑,2,   ChemoSideEff↓,1,   cognitive↑,2,   COX2↓,5,   CRP↓,1,   CXCR2↑,1,   Cyt‑c↓,1,   DNMT1↓,1,   DNMT3A↓,1,   Dose↑,1,   Dose↝,2,   E2Fs↑,1,   eff↑,6,   ER Stress↓,2,   FAO↑,1,   GPx↑,4,   GR↑,1,   GSH↑,7,   GSK‐3β↓,1,   GSR↑,1,   GSTA1↑,1,   GSTs↑,3,   Half-Life↑,2,   Half-Life↝,2,   Half-Life∅,1,   HDAC↓,12,   HDAC3↓,2,   HDL↑,1,   hepatoP↓,1,   hepatoP↑,1,   HO-1↑,2,   hs-CRP↓,1,   HSP27↓,1,   IAP1↓,1,   IFN-γ↓,1,   IGF-1R↓,1,   IKKα↑,1,   IL10↓,1,   IL10↑,1,   IL17↓,2,   IL1β↓,6,   IL22↓,1,   IL6↓,4,   IL8↓,2,   Inflam↓,9,   Inflam↑,1,   iNOS↓,4,   JAK↓,1,   JNK↓,1,   Ki-67↓,1,   LDH↓,1,   LDL↓,1,   lipid-P↓,2,   lipoGen↓,1,   Mag↑,1,   MAPK↓,1,   MDA↓,2,   memory↑,3,   MMP13↓,1,   MMP2↓,1,   MPO↑,1,   NA↓,1,   NAD↑,1,   NAD↝,1,   NADPH↓,1,   neuroP↑,9,   NF-kB↓,6,   NH3↓,1,   NO↓,2,   NQO1↑,1,   Nrf1↑,1,   NRF2↑,6,   other↓,1,   P-gp↓,1,   P21↓,1,   P450↓,1,   P53↓,1,   PDGFR-BB↓,1,   PGC-1α↓,1,   PGE2↓,2,   PTEN↑,1,   p‑Rac1↓,1,   radioP↑,2,   RenoP↑,2,   Risk↓,1,   RNS↓,1,   ROS↓,16,   ROS∅,1,   SAM-e↑,1,   selectivity↑,1,   serineP↓,1,   SIRT1↑,2,   SOD↑,6,   SOD1↑,1,   SOD2↑,2,   TBARS↓,1,   testos↑,1,   TIMP1↓,1,   TNF-α↓,9,   toxicity↓,7,   toxicity↝,1,   toxicity∅,2,   VEGF↑,1,   VitC↑,1,   VitD↑,1,  
Total Targets: 128

Scientific Paper Hit Count for: HDAC, Histone deacetylases
30 Sulforaphane (mainly Broccoli)
23 Phenylbutyrate
13 Thymoquinone
9 EGCG (Epigallocatechin Gallate)
7 Apigenin (mainly Parsley)
4 Butyrate
4 Chrysin
4 Chemotherapy
4 Luteolin
4 Quercetin
3 Berberine
3 Boron
3 Honokiol
3 Resveratrol
3 Silymarin (Milk Thistle) silibinin
2 Ashwagandha
2 Curcumin
2 Cisplatin
2 Propolis -bee glue
1 Allicin (mainly Garlic)
1 alpha Linolenic acid
1 Andrographis
1 Betulinic acid
1 diet FMD Fasting Mimicking Diet
1 Genistein
1 Magnolol
1 Radiotherapy/Radiation
1 Piperlongumine
1 Vorinostat
1 Selenite
1 doxorubicin
1 Gemcitabine (Gemzar)
1 Vitamin D3
1 diet Plant based
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:140  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page